ArticleGalen medical journal2024
Protective Effect of Naringin in L-arginine-induced Acute Pancreatitis in Wistar Rats.
Article in Galen medical journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAcute pancreatitis, a non-infectious inflammatory disorder of the pancreas, is not only the most common cause of hospitalization among gastrointestinal diseases in many countries but up to 20% of patients may experience morbidity and mortality. Naringin is a common flavonoid that is found in many fruits such as oranges and tomatoes, and evidence revealed its use in the prevention and treatment of many diseases due to its antioxidant and anti-inflammatory effects. Hence, this study was conducted to investigate the anti-inflammatory and antioxidant effects of naringin in the pancreatitis model in rats. MATERIALS AND
methodsIn this experimental study, sixty male Sprague-Dawley rats were divided into 4 equal groups. In the control group, normal saline was injected intraperitoneally (IP). In the sham and experimental groups, pancreatitis was induced with a dose of 3.2 g/kg body weight of L-arginine IP, twice with a time interval of one hour. Rats of low dose (E-L) and high dose (E-H) groups were treated with 200 and 500 mg/kg of naringin IP, 30 minutes before L-arginine administration, respectively. Serum lipase and amylase along with pancreatic IL-10, IL-1β, and TNF-α were measured. Also, to evaluate oxidative stress, pancreatic superoxide dismutase (SOD), glutathione (GSH), malondialdehyde (MDA), and myeloperoxidase (MPO) were evaluated. In addition, the histopathological study was performed with morphological examination.
resultsSham rats exhibited increased levels of amylase and lipases compared to controls. Naringin administration significantly reduced these levels in the experimental groups. In addition, naringin decreased MDA and MPO levels and increased SOD and GSH activities in the E-L and E-H groups. TNF-α and IL-1β levels were higher in the sham group but reduced with naringin treatment. Naringin also increased IL-10 levels in a dose-dependent manner. Histopathological analysis showed that naringin reduced tissue damage severity in a dose-dependent manner.
conclusionBased on the results obtained in the study, naringin administration effectively reduced pancreas enzyme activity, and increased antioxidant enzyme activities in rats with induced pancreatitis. Naringin also exhibited anti-inflammatory effects by decreasing TNF-α and IL-1β levels while increasing IL-10 levels in a dose-dependent manner. Moreover, the histopathological analysis demonstrated that naringin had protective effects against tissue damage caused by pancreatitis, showing a dose-dependent reduction in the severity of edema, inflammation, and necrosis. These findings suggest that naringin holds promise as a potential therapeutic agent for managing pancreatitis-related complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.